Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology

哺乳动物中的组氨酸磷酸化:调节、蛋白质靶点和生物学

基本信息

项目摘要

Project Summary Whereas phosphorylation of serine, threonine and tyrosine are exceedingly well characterized, relatively little is known about phosphorylation of histidine (His), which may account for as much as ~6% of all incorporation of phosphate into mammalian proteins. We have provided genetic and biochemical evidence that the histidine kinase, NDPK-B, and the histidine phosphatases (PTases), PHPT1 and (PGAM5, regulate the activity of the Ca2+-activated K+ channel KCa3.1 by reversible His phosphorylation, and thereby the activation of CD4 T and mast cells. While NDPK-B His phosphorylates and activates KCa3.1, PGAM5 and PHPT1 inhibit KCa3.1 His phosphorylation by specifically dephosphorylating and inhibiting NDPK-B and KCa3.1 respectively. Using recently developed monoclonal antibodies to 1- and 3-phospho-Histidine (pHis), we demonstrate for the first time the regulation of histidine phosphorylation in vivo in mammalian cells, which we in turn linked to TCR signaling. SA1 we will build on these studies, we will assess changes in His phosphorylation of NDPK-B and KCa3.1 in the context of TCR signaling, determine how it is regulated by various signaling molecules such as PI3KC2, whether other pHis proteins are present in T cells and/or regulated by TCR signaling, and the specific role for PGAM5, PHPT1 and NDPK-B to modulate changes in pHis proteins. We have found that the 24 cleaved PGAM5-L isoform is most critical to dephosphorylate NDPK-B. We will determine whether the 24 cleaved PGAM5-L isoform negatively regulates CD4 T cells in vivo, whether the amount of this isoform changes following TCR stimulation, and the intramembranous proteases that mediates cleavage in CD4 T cells. We also identified a critical role for histidine phosphorylation in pancreatic  cell function. We found that  cells from PHPT1-/- mice have electrical properties similar to those of patients with mutations in KATP channel subunits and KATP channel-/- mice. The defect in PHPT1-/- β cells can be explained by the failure of KATP channels to relocalize from an intracellular compartment to the plasma membrane (PM) in response to low glucose and leptin and we have now linked the defect in PHPT1-/- β cells to impaired activation of transient receptor potential channel 4 (TRPC4). Our hypothesis is that reversible His phosphorylation of TRPC4 by PHPT1, NDPK-B, PGAM5 regulates TRPC4 channel activity in a similar manner to KCa3.1, albeit in opposite directions; whereas His phosphorylation of KCa3.1 activates, His phosphorylation of TRPC4 inhibits. In SA 2, we will determine if PHPT1, NDPK-B, and PGAM5 regulate His phosphorylation of TRPC4 in a manner similar to KCa3.1, their role in KATP channel trafficking and TRPC4 activation, and whether decreased KATP trafficking to the PM in TRPC4-/- and PGAM5-/- mice leads congenital hyperinsulinemia hypoglycemia that is similar to PHPT-/- mice and patients with CHI. We will then extend these studies to human  cells and assess the potential relevance of these molecules to human disease that include CHI and type 2 diabetes mellitus.
项目摘要 尽管丝氨酸、苏氨酸和酪氨酸的磷酸化非常好地表征,相对而言, 组氨酸(His)的磷酸化可能占所有掺入的约6%,但对它的了解很少 磷酸盐转化成哺乳动物蛋白质。我们已经提供了遗传和生化证据, 激酶NDPK-B和组氨酸磷酸酶(PTases)PHPT 1和(PGAM 5)调节细胞的活性。 Ca 2+通过可逆的His磷酸化激活K+通道KCa3.1,从而激活CD 4 T细胞, 肥大细胞NDPK-B His磷酸化激活KCa 3.1,而PGAM 5和PHPT 1抑制KCa 3.1 His 通过特异性地去磷酸化和抑制NDPK-B和KCa 3.1来抑制磷酸化。使用 最近开发的单克隆抗体1-和3-磷酸组氨酸(pHis),我们首次证明 哺乳动物细胞中组氨酸磷酸化的调节,我们又将其与TCR信号传导联系起来。 SA 1我们将在这些研究的基础上,我们将评估NDPK-B和KCa 3.1的His磷酸化的变化, TCR信号传导的背景下,确定它是如何调节各种信号分子,如PI 3 KC 2 β,是否 其它pHis蛋白存在于T细胞中和/或受TCR信号传导调节,而PGAM 5, PHPT 1和NDPK-B调节pHis蛋白的变化。我们已经发现,PGAM 5-L的124切割 同种型对NDPK-B去磷酸化最关键。我们将确定PGE 24是否切割PGAM 5-L 同种型在体内负调节CD 4 T细胞,无论该同种型的量在TCR后是否改变, 刺激,以及介导CD 4 T细胞裂解的膜内蛋白酶。 我们还确定了组氨酸磷酸化在胰腺癌细胞功能中的关键作用。我们发现 来自PHPT 1-/-小鼠的EPCs细胞具有与KATP通道突变患者相似的电特性 亚基和KATP通道-/-小鼠。PHPT 1-/- β细胞的这种缺陷可以通过KATP通道的失效来解释 响应于低葡萄糖从细胞内区室重新定位到质膜(PM), 我们现在已经将PHPT 1-/- β细胞中的缺陷与瞬时受体电位激活受损联系起来 通道4(TRPC 4)。我们的假设是,TRPC 4的可逆His磷酸化通过PHPT 1,NDPK-B, PGAM 5以与KCa 3.1类似的方式调节TRPC 4通道活性,尽管方向相反; His对KCa3.1的磷酸化激活,His对TRPC 4的磷酸化抑制。在SA 2中,我们将确定 PHPT 1、NDPK-B和PGAM 5以类似于KCa 3.1的方式调节TRPC 4的His磷酸化,它们的作用 在KATP通道运输和TRPC 4激活中,以及在TRPC 4-/- PGAM 5-/-小鼠导致与PHPT-/-小鼠和患者相似的先天性高胰岛素血症低血糖 在CHI。然后,我们将把这些研究扩展到人类胰岛细胞,并评估这些研究的潜在相关性。 分子对人类疾病包括CHI和2型糖尿病的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD Y SKOLNIK其他文献

EDWARD Y SKOLNIK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD Y SKOLNIK', 18)}}的其他基金

Identification of new therapeutic targets for ADPKD
ADPKD 新治疗靶点的确定
  • 批准号:
    10462701
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Identification of new therapeutic targets for ADPKD
ADPKD 新治疗靶点的确定
  • 批准号:
    10629396
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Identification of new therapeutic targets for ADPKD
ADPKD 新治疗靶点的确定
  • 批准号:
    10298937
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology
哺乳动物中的组氨酸磷酸化:调节、蛋白质靶点和生物学
  • 批准号:
    10395477
  • 财政年份:
    2019
  • 资助金额:
    $ 39.83万
  • 项目类别:
Identification and characterization of a novel mammalian histidine phosphatase that negatively regulates CD4 T cells
负调节 CD4 T 细胞的新型哺乳动物组氨酸磷酸酶的鉴定和表征
  • 批准号:
    9330534
  • 财政年份:
    2016
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8667953
  • 财政年份:
    2013
  • 资助金额:
    $ 39.83万
  • 项目类别:
New Signaling pathways that positively and negatively regulate CD4 T cells via th
通过 th 正向和负向调节 CD4 T 细胞的新信号通路
  • 批准号:
    8742789
  • 财政年份:
    2013
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8541082
  • 财政年份:
    2012
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8218480
  • 财政年份:
    2012
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8875012
  • 财政年份:
    2012
  • 资助金额:
    $ 39.83万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Operating Grants
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了